The MET Oncogene: An Update on Targeting Strategies

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The MET receptor tyrosine kinase (RTK), also known as the hepatocyte growth factor (HGF) receptor, plays vital roles in embryonic development and tissue repair.
• Aberrant MET signaling, often due to genetic alterations, is implicated in tumorigenesis, metastasis, and cancer progression, promoting invasive growth.
• Understanding MET signaling pathways is critical for developing targeted cancer therapies.

Purpose of the Study:

• To provide an updated overview of therapeutic strategies targeting MET signaling in cancer.
• To highlight novel drug candidates and their mechanisms of action against MET-driven cancers.

Main Methods:

• Literature review of scientific publications and clinical trial data.
• Analysis of drug development pipelines focusing on MET modulators.
• Synthesis of information on various therapeutic classes targeting MET.

Main Results:

• Identification of diverse therapeutic agents including MET kinase inhibitors, degraders, monoclonal antibodies, and antibody-drug conjugates.
• Demonstration of MET signaling's complex role in cancer initiation, progression, and metastasis.
• Highlighting the potential of MET-targeted therapies in oncology.

Conclusions:

• Targeting MET signaling offers a promising avenue for developing effective anti-cancer treatments.
• Continued research into MET-targeted therapies is essential for advancing cancer care.
• The reviewed therapeutic approaches represent significant progress in combating MET-driven malignancies.